Pre-made Ulocuplumab benchmark antibody ( Whole mAb, anti-CXCR4 therapeutic antibody, Anti-FB22/HM89/LAP3/LCR1/NPYR/WHIM/CD184/LAP-3/LESTR/NPY3R/NPYRL/WHIMS/HSY3RR/NPYY3R/WHIMS1/D2S201E Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ulocuplumab biosimilar, Whole mAb, Anti-CXCR4 Antibody: Anti-FB22/HM89/LAP3/LCR1/NPYR/WHIM/CD184/LAP-3/LESTR/NPY3R/NPYRL/WHIMS/HSY3RR/NPYY3R/WHIMS1/D2S201E therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ulocuplumab (INN; development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-600-1mg	1mg	3090
GMP-Bios-ab-600-10mg	10mg	Inquiry
GMP-Bios-ab-600-100mg	100mg	Inquiry
GMP-Bios-ab-600-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ulocuplumab biosimilar, Whole mAb, Anti-CXCR4 Antibody: Anti-FB22/HM89/LAP3/LCR1/NPYR/WHIM/CD184/LAP-3/LESTR/NPY3R/NPYRL/WHIMS/HSY3RR/NPYY3R/WHIMS1/D2S201E therapeutic antibody
INN Name	Ulocuplumab
Target	CXCR4
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Bristol-Myers Squibb;Medarex;University of Bari
Conditions Approved	na
Conditions Active	Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours
Conditions Discontinued	B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma
Development Tech	na